These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 34838310)
1. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort. Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310 [TBL] [Abstract][Full Text] [Related]
2. Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes. Prathibha S; White M; Kolbow M; Hui JYC; Brauer D; Ankeny J; Jensen EH; LaRocca CJ; Marmor S; Tuttle TM Breast Cancer Res Treat; 2024 May; 205(1):127-133. PubMed ID: 38281296 [TBL] [Abstract][Full Text] [Related]
3. [Strategies in case of metastatic sentinel lymph node in breast cancer]. Costaz H; Rouffiac M; Boulle D; Arnould L; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Vincent L; Jankowski C; Coutant C Bull Cancer; 2020 Jun; 107(6):672-685. PubMed ID: 31699399 [TBL] [Abstract][Full Text] [Related]
4. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155 [TBL] [Abstract][Full Text] [Related]
5. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379 [TBL] [Abstract][Full Text] [Related]
6. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice? Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437 [TBL] [Abstract][Full Text] [Related]
7. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials. Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752 [TBL] [Abstract][Full Text] [Related]
8. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort. Riedel F; Heil J; Feißt M; Rezai M; Moderow M; Sohn C; Schütz F; Golatta M; Hennigs A Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814 [TBL] [Abstract][Full Text] [Related]
9. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort. Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659 [TBL] [Abstract][Full Text] [Related]
10. Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis. Caretta-Weyer H; Greenberg CG; Wilke LG; Weiss J; LoConte NK; Decker M; Steffens NM; Smith MA; Neuman HB Ann Surg Oncol; 2013 Dec; 20(13):4145-52. PubMed ID: 23959051 [TBL] [Abstract][Full Text] [Related]
11. The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials. Ortega Expósito C; Falo C; Pernas S; Pérez Carton S; Gil Gil M; Ortega R; Pérez Montero H; Stradella A; Martinez E; Laplana M; Salinas S; Luzardo A; Soler T; Fernández Montoli ME; Azcarate J; Guma A; Petit A; Benitez A; Bajen M; Reyes Junca JG; Campos M; Ruiz R; Ponce J; Pla MJ; García Tejedor A Breast Cancer Res Treat; 2021 Aug; 189(1):111-120. PubMed ID: 34089119 [TBL] [Abstract][Full Text] [Related]
12. Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology. Mattar D; Di Filippo A; Invento A; Radice D; Burcuta M; Bagnardi V; Magnoni F; Santomauro G; Corso G; Mazzarol G; Viale G; Sacchini V; Galimberti V; Veronesi P; Intra M Eur J Surg Oncol; 2021 Oct; 47(10):2499-2505. PubMed ID: 34172359 [TBL] [Abstract][Full Text] [Related]
13. [Impact of omission of axillary dissection on adjuvant therapy in patients with metastatic sentinel lymph nodes according to the ACOSOG Z0011 criteria]. Roosen A; Lousquy R; Bricou A; Delpech Y; Selz J; Le Maignan C; Bousquet G; Winterman S; Zelek L; Barranger E Gynecol Obstet Fertil; 2014 Jun; 42(6):409-14. PubMed ID: 24861437 [TBL] [Abstract][Full Text] [Related]
14. Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study. Peng Y; Liu M; Li X; Tong F; Cao Y; Liu P; Zhou B; Liu H; Cheng L; Guo J; Xie F; Yang H; Wang S; Wang C; Chen Y; Wang S World J Surg Oncol; 2021 Apr; 19(1):128. PubMed ID: 33879180 [TBL] [Abstract][Full Text] [Related]
15. Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACOSOG Z0011 trial. Tseng J; Alban RF; Siegel E; Chung A; Giuliano AE; Amersi FF Breast J; 2021 Mar; 27(3):216-221. PubMed ID: 33586201 [TBL] [Abstract][Full Text] [Related]
16. Omission of axillary dissection according to ACOSOG Z0011: impact on adjuvant treatment recommendations. Aigner J; Smetanay K; Hof H; Sinn HP; Sohn C; Schneeweiss A; Marmé F Ann Surg Oncol; 2013 May; 20(5):1538-44. PubMed ID: 23389469 [TBL] [Abstract][Full Text] [Related]
18. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases. Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771 [TBL] [Abstract][Full Text] [Related]
19. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients. Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212 [TBL] [Abstract][Full Text] [Related]
20. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy. Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]